Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) Return on Sales (2016 - 2025)

Regenxbio has reported Return on Sales over the past 12 years, most recently at 2.21% for Q4 2025.

  • Quarterly results put Return on Sales at 2.21% for Q4 2025, up 20.0% from a year ago — trailing twelve months through Dec 2025 was 1.14% (up 159.0% YoY), and the annual figure for FY2025 was 1.14%, up 159.0%.
  • Return on Sales for Q4 2025 was 2.21% at Regenxbio, down from 2.08% in the prior quarter.
  • Over the last five years, Return on Sales for RGNX hit a ceiling of 7.03% in Q4 2022 and a floor of 4.06% in Q1 2024.
  • Median Return on Sales over the past 5 years was 2.44% (2024), compared with a mean of 1.94%.
  • Biggest five-year swings in Return on Sales: skyrocketed 629bps in 2022 and later crashed -987bps in 2023.
  • Regenxbio's Return on Sales stood at 0.74% in 2021, then skyrocketed by 853bps to 7.03% in 2022, then plummeted by -140bps to 2.83% in 2023, then rose by 15bps to 2.42% in 2024, then grew by 8bps to 2.21% in 2025.
  • The last three reported values for Return on Sales were 2.21% (Q4 2025), 2.08% (Q3 2025), and 3.32% (Q2 2025) per Business Quant data.